The aim of the present study was to gain insight into the pathophysiology of obesity by comparing the pattern of gene expression of omental adipose tissue of obese and lean volunteers using DNA microarrays. Omental adipose tissue biopsies were obtained by laparoscopic surgery from six male patients (44.2±6.3 yr). RNA was extracted and pooled for the obese (BMI: 37.3±2.5 kg/m 2 ) and lean (BMI: 23.4±0.8 kg/m 2 ) groups. From the total number of genes analyzed (1,152 well-characterized human genes), 41% were expressed at sufficient levels in human adipose tissue for detection in the microarray experiments, finding that 89 genes were upregulated while 64 were down-regulated at least twofold in the omental adipose tissue obtained from obese patients. We found a general tendency to blunt lipolysis inducer genes and a global down-regulation of genes encoding growth factors. Moreover, an up-regulation in the expression of several mitogen-activated protein kinases (MAPKs) was observed. The down-regulation of genes involved in lipolysis activation may be involved in the etiopathogenesis of obesity. In addition, down-regulation of growth factors and the up-regulation of MAPKs may indicate an attempt to restrain adipocyte proliferation and differentiation. Furthermore, obesity is accompanied by an altered expression in omental adipose tissue of genes involved not only in energy homeostasis but also in quite diverse biological functions, such as immune response. The genomic approach underlines the importance of adipose tissue beyond energy metabolism.
Obesity is defined medically as a state of increased adipose tissue of sufficient magnitude to produce adverse health consequences (4) (5) (6) . However, the molecular mechanisms that lead to and take part in the development of obesity and the hyperplasia and hypertrophy of adipose tissue are not well understood. Until recently adipose tissue had been only considered to be a passive tissue for the storage of excess energy as triglycerides in order to provide energy for situations of negative energy balance. It has however been clearly established that adipose tissue secretes a wide variety of biologically active molecules at the same time as expresses receptors for numerous hormones and cytokines among others, thus representing an extremely active endocrine organ (7, 8) . Although adipocytes have been shown to express more genes than initially thought (6, 9, 10) , no large-scale genomic studies have been performed in humans comparing the expression profile between obese and lean subjects.
Oligonucleotide or cDNA microarrays have dramatically changed the study of the pattern of gene expression by enabling the simultaneous analysis of thousands of genes in a single experiment. For this reason, gene expression profiling by microarrays represents a valuable tool to identify new players in complex pathophysiological processes, such as obesity (11) (12) (13) .
In the present work, we analyzed the effect of obesity on the gene expression profile of human omental adipose tissue by using DNA microarrays. We focused on omental adipose tissue because it has been shown that fat from this location is more closely involved in the comorbidities associated to obesity than fat from the subcutaneous depot (14) . Our data provide novel information for the identification of genes that may be implicated in the pathological consequences of obesity or involved in the genetic susceptibility to obesity development.
METHODS

Human subjects and adipose tissue biopsy
Omental adipose tissue and blood samples were obtained from six male patients undergoing either laparoscopic bariatric surgery or laparoscopic Nissen fundoplication at the Clínica Universitaria de Navarra. The samples were immediately frozen in liquid nitrogen and stored at -85°C for gene expression analysis. Patients were classified as lean or obese according to both body mass index (BMI) and body fat. BMI was calculated as weight in kilograms divided by the square of height in meters. Body fat was estimated by air-displacement-plethysmography (BodPod ® , Life Measurements, Concord, CA) (15) . Obesity was defined as BMI ≥30 kg/m 2 and body fat >25%. Impaired glucose tolerance [fasting plasma glucose ≥110 mg/dl and <126 mg/dl or ≥140 mg/dl and <200 mg/dl 2 h after an oral glucose tolerance test (OGTT)], diabetes mellitus (fasting plasma glucose ≥126 mg/dl or ≥200 mg/dl 2 h after an OGTT), hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), or pharmacological treatment was exclusion criteria for both groups. Informed consent was obtained from all patients after the nature of the study was explained, and the experimental design was approved, from an ethical and scientific standpoint, by the Hospital's Ethical Committee responsible for research.
Blood assays
Blood was obtained by venipuncture before surgery. To avoid potential confounding influences due to the effect of circadian rhythms on gene expression (16) , fat samples were obtained between 8.30 to 12.00 a.m. Serum glucose was analyzed by an automated analyzer (Roche/Hitachi Modular P800), with quantification being based on enzymatic colorimetric reactions. Serum insulin was measured by means of an enzyme-amplified chemiluminescence assay (IMMULITE ® , Diagnostic Products Corp., Los Angeles, CA). The homeostasis model assessment (HOMA) score of insulin sensitivity was calculated with the formula: fasting serum insulin (µU/ml) x fasting plasma glucose (mmol/l)/22.5 (17) . Total cholesterol and triglyceride concentrations were determined by enzymatic spectrophotometric methods (Boehringer Mannheim, Mannheim, Germany). High-density lipoprotein (HDL) cholesterol was quantified by a colorimetric method in a Beckman Synchron ® CX analyzer (Beckman Instruments, Ltd., Bucks, UK). Low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald formula. Apolipoprotein A-1 and -B and lipoprotein(a) were measured by nephelometric tests (IMMAGE ® Immunochemistry Systems, Beckman Instruments, Ltd.). Serum free fatty acids concentrations were quantified by an enzymatic method (NEFA-C, ACS-ACOD Method, Wako Chemicals, Neuss, Germany). Uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (γ-GT), and alkaline phosphatase were measured by enzymatic tests (Roche, Basel, Switzerland) in an automated analyzer (Roche/Hitachi Modular P800). Urea concentrations were analyzed by means of a Beckman Synchron LX analyzer (Beckman Instruments, Ltd.). Adenosine deaminase (ADA) was determined by an enzymatic test (Biomerieux, Marcy L'Etoile, France).
Leptin was measured by a double-antibody RIA method (Linco Research, Inc., St. Charles, MO). Intra-and interassay coefficients of variation were 5 and 4.5%, respectively. Glucagon was measured by a double-antibody RIA method (Medgenix Diagnostics, Fleurus, Belgium). Thyroid hormones were measured by immunoassays (AxSYM, Abbott Laboratories, Abbott Park, IL). Free insulin-like growth factor 1 (IGF-1) was determined by a commercially available immunoradiometric assay (Diagnostic Systems Laboratories, Inc., Webster, TX). Free testosterone concentrations were measured using a competitive immunoassay (Diagnostic Systems Laboratories).
Fibrinogen concentrations were determined according to the method of Clauss using a commercially available kit (Hemoliance ® , Instrumentation Laboratory, Barcelona, Spain). Measurement of von Willebrand factor antigen was performed by a micro-latex immunoassay (Diagnostica Stago, Inc., Parsippany, NJ). A standard curve was prepared with a universal reference (NISBC 91/666), and the results were expressed as percentage of the standard. Intraand interassay coefficients of variation were between 4 and 8%. The concentrations of C-reactive protein (CRP) were analyzed by means of an immunoturbidimetric assay (Boehringer Mannheim) after calibration with the standard CRM 470. Homocysteine was determined applying a fluorescence polarization immunoassay (Axis Biochemicals ASA, Oslo, Norway), using an IMx ® analyzer (Abbott Laboratories).
RNA preparation
Total RNA was extracted from each human fat sample by homogenization with an ULTRA-TURRAX ® T 25 basic (IKA ® Werke GmbH, Staufen, Germany) using TRIzol reagent (Life Technologies, Gaithersburg, MD). After treatment with DNase I (Roche), equal amounts of total RNA pooled from each group of subjects were reverse transcribed to cDNA by using cDNA Synthesis System (Roche) with an oligo[(dT) 24 T7prom] 65 primer incorporating a T7 RNA polymerase promoter. After synthesis of second-strand cDNA and digestion of template RNA, double-stranded cDNA was extracted by phenol-chloroform-isoamyl alcohol and precipitated with ethanol. Biotin-labeled cRNA was synthesized from cDNA using the T7 MEGAscript™ Kit (Ambion, Austin, TX) and purified with Micro-Spin Columns (Mergen Ltd., San Leandro, CA). cRNA was fragmented to sizes ranging 30-100 bases, and 20 µg of RNA fragments were hybridized to the microarrays.
Microarray experiments and analysis
The HO1 Express Chip™ DNA Microarray System (Mergen Ltd.) contains 30-mer oligonucleotides specific for 1,152 well-characterized human genes. The array includes diluted series of housekeeping genes (GAPDH, phospholipase A2, α-tubulin, and ubiquitin C), mutated sequences to serve as negative controls, and a number of duplicates for quality control. Gene information on each arrayed spot and links to NCBI GenBank/UniGene databases are accessible from the Mergen Ltd. website (http://www.mergen-ltd.com). Given the fact that the commercial array used did not contain some of the well-studied obesity-related genes, we assessed the expression of leptin, one of the best known genes, the expression of which is altered in obesity, as a control of obesity-induced changes on mRNA expression. In accordance with the literature (18), we found a >100% up-regulation in the mRNA expression of leptin in the omental adipose tissue of the obese patients as compared with the lean subjects.
Hybridization to human microarrays was performed for 16 h at 30°C in a custom-built hybridization chamber with constant rotation. The arrays were washed and then incubated sequentially with streptavidin, anti-streptavidin antibody, and Cy3-conjugated second antibody. Microarrays were scanned using an Affymetrix/GMS 418 scanner (Genetic MicroSystems Inc., Woburn, MA). The mean of the intensities of the pixels of a spot and of the local background around this spot was analyzed by using the ImaGene 4.0 analysis suite software (BioDiscovery, Marina del Rey, CA). The data were adjusted by using the global intensity of fluorescence of the arrays to normalize varying efficiencies of labeling and detection. Cut-off values for each spot were automatically calculated according to their local background. The ratio obese/lean of normalized emission signals was calculated for each gene in the arrays. Genes with expression fold change ≥2 were classified according to the biological process in which they are involved following the criteria of the Gene Ontology Consortium (GO) (19) .
Semiquantitative RT-PCR
To validate the obtained microarray data, a number of representative differentially expressed genes were selected for validation by RT-PCR and were individually studied in samples from the same lean individuals and obese patients than those used for the microarray study. One microgram of RNA was used to synthesize first-strand cDNA after treatment with DNase I (Roche). The RT reaction was carried out in a volume of 20 µl containing 200 units of M-MLV RT (Gibco-BRL, Life Technologies) and incubated at 37°C for 60 min. Four microliters from the RT reaction were amplified in a 50 µl reaction mixture containing 40 ng of each primer and 1 unit of BIOTAQ™ polymerase (Bioline). Primers used to amplify cDNA are indicated in Table 1 and were designed using the Oligo ® 4.05 Primer Analysis Software (National Biosciences, Inc., Plymouth, MN). cDNA was amplified for the number of cycles reported in Table 1 , using the following parameters: 94°C for 30 s, 30 s at annealing temperature (Table 1) , and 72°C for 30 s, with a final extension step at 72°C for 7 min. Amplifications were linear under these conditions and were carried out in a GeneAmp ® PCR System 2400 (Perkin Elmer, Norwalk, CT). All PCR reactions for each gene were performed at the same time and with the same batch of Taq polymerase to reduce variations in the efficiency of PCR. The amplified products were resolved in a 1.5% agarose gel with ethidium bromide. VEGFB cDNA amplification yielded two bands of 430 and 531 bp corresponding to the VEGFB 167 and VEGFB 186 isoforms generated by alternative splicing of the VEGFB gene (20) , and their identity was confirmed by sequencing. Levels of mRNA were expressed as the ratio of signal intensity for each gene relative to that for β-actin (UniGene symbol ACTB, GenBank X00351). The ratio of each gene/ACTB in the lean group was assumed to be 1. The intensity of the PCR bands was determined by densitometric analysis with the Gel Doc 1000 UV fluorescent gel documentation system and Molecular Analyst 1.4.1 software for quantitation of images (Bio-Rad, Hercules, CA).
Statistical analysis
Data are means ± SE. Differences between the lean and obese groups were analyzed by U MannWhitney's tests. A P value <0.05 was considered statistically significant. The calculations were performed using the SPSS/Windows version 11.0.1 statistical package (SPSS, Chicago, IL).
RESULTS
The clinical characteristics of the study subjects are presented in Table 2 . Obese subjects had BMI values >30 kg/m 2 as well as a body fat >35%. Although glucose concentrations were slightly higher in the obese group, all values were within the normal range (<7.0 mmol/l). In addition, no differences in insulin concentrations and HOMA scores were observed. Compared with the lean subjects the obese patients were hyperuricemic as well as slightly hypertriglyceridemic and hypercholesterolemic with higher serum concentrations of LDLcholesterol, apolipoprotein B, and lipoprotein(a). Obese patients exhibited a normal liver and endocrine function. Cardiovascular risk factors were within the normal range, except for fibrinogen concentrations, which were slightly increased in the obese individuals.
Among the 1152 well-characterized genes analyzed, 41% were expressed at sufficient levels in human adipose tissue for detection in the microarray experiments, in addition to the 10% embodying housekeeping genes, duplicates, and negative controls. From the 153 genes with a more than twofold variation, 89 (8% of the total number) were up-regulated (Table 3 ) and 64 (6% of the total number) were down-regulated (Table 4 ). The genes with a greater than twofold variation were classified into categories depending on the biological process in which they are involved according to the criteria of GO (19) .
The set of genes with altered expression in omental adipose tissue of obese humans represents a broad spectrum of biological processes. The majority of the genes with altered expression encodes proteins involved in cell proliferation, immune response, angiogenesis, metabolism, and signal transduction, most of them not described previously to be involved in obesity. Our study shows the up-regulation of several genes involved in the immune response, mainly receptors for Fc fragment of IgG, in the adipose tissue of obese patients. Interestingly, genes participating in the control of metabolism, such as adrenergic β receptor kinase 2 (ADRBK2), low-density lipoprotein receptor-related protein 5 (LRP5), glycogen synthase kinase 3-α (GSK3A), and phosphoglycerate kinase 1 (PGK1) were up-regulated, whereas others involved in diverse biochemical pathways such as low-density lipoprotein receptor (LDLR), androgen receptor (AR), and prostaglandin E receptor 3 (PTGER3) were down-regulated. Relevant genes for food intake and energy metabolism regulation such as neuropeptide Y (NPY) receptors Y1 (NPY1R) and Y5 (NPY5R) showed an increased mRNA expression in obese patients. Several members of the mitogen-activated protein kinase (MAPK) cascade such as MAPK3, MAP3K4, MAPK9, and MAP2K6 exhibited an increased expression, whereas other important genes with signal transducing functions such as insulin receptor substrate 4 (IRS4), natriuretic peptide receptor C (NPR3), Janus kinase 2 (JAK2), and adrenergic β-2-receptor (ADRB2) were depressed. Expression of genes involved in preadipocyte proliferation and differentiation such as IGF1, fibroblast growth factors FGF2, 4, and 7 was decreased. Of special interest were the changes observed in angiogenic factors. Whereas vascular endothelial growth factor B (VEGFB) and FGF1 were up-regulated, c-fos induced growth factor (vascular endothelial growth factor D) (FIGF) was down-regulated.
The partial distribution of differentially expressed genes according to the chromosome they are mapped to is shown in Fig. 1 . Chromosomes 1, 11, and 19 showed the highest number of genes with changed expression in omental adipose tissue from obese patients, whereas chromosomes 8, 13, 18, 21, and 22 were those to which a smaller amount of changed genes are mapped.
To confirm the microarray data, the mRNA expression of a number of representative transcripts involved in metabolism, cell proliferation, immune response, and signal transduction with differential expression was analyzed. Semiquantitative RT-PCR assays were carried out to measure their mRNA levels in biopsies from the obese and lean individuals. The mRNA level of AR, Fc fragment of IgG, low affinity IIIb (FCGR3B), MAPK3, NPY1R, NPY5R, and VEGFB was determined (Table 5 ). For each of the genes, mRNA levels showed similar trends to those obtained in the microarray experiment. In accordance with the microarray results, AR was downregulated by 50%, whereas FCGR3B, MAPK3, NPY1R, NPY5R, as well as VEGFB 167 and VEGFB 186 increased their expression by ~130, 40, 50, 40, 60, and 110%, respectively, in obese patients compared with lean control subjects. To further validate the consistency of the microarray data, the expression of some selected genes was assessed in a subset of adipose tissue samples obtained from other obese patients (n=4) and lean subjects (n=2) of similar clinical characteristics to those used in the array experiments. The changes in gene expression were confirmed in this subset of individuals showing a down-regulation by 60% of AR expression in adipose tissue of obese patients, while NPY1R and NPY5R expression was up-regulated 150 and 120%, respectively.
DISCUSSION
Given the epidemic proportions reached by obesity worldwide (1), there is a need for a better knowledge of dysregulated genes, which may be a cause of or involved in the development of obesity. In the present work, the gene expression profile of omental adipose tissue in human obesity was analyzed by using oligonucleotide microarrays. Among the well-characterized genes included in the array, 41% were expressed at sufficient levels in human adipose tissue for detection in the microarray experiments. This proportion is similar to that found in a recently published study performed in visceral adipose tissue obtained from only one nonobese subject (21) . Our analysis comparing omental adipose tissue of nondiabetic, normotensive, obese patients with that of lean subjects has identified 153 genes with an altered expression in obesity. Interestingly, the majority of genes with an altered expression has not been described previously to be involved in obesity and most of them encode proteins involved in cell proliferation, metabolism, signal transduction pathways, as well as immune and inflammatory responses.
A key factor in energy balance is the mobilization of lipids through lipolysis in fat cells (6, 22) , and alterations in this process have been associated with obesity (23) . In this respect, it is noteworthy that our study shows a decreased expression of ADRB2, an adrenergic receptor the catecholamine-induced stimulation of which exerts a strong lipolytic action (22) , and an increased expression of ADRBK2, a protein involved in the desensitization of β-adrenergic receptors (24) . NPY, a neurotransmitter involved in food intake and body weight regulation, has been also shown to be a powerful antilipolytic agent (25) . Transcripts of the main receptors for NPY involved in body weight regulation (i.e., NPY1R and NPY5R) were readily detectable in our experiments in accordance with previous reports (26) . The expression of both genes was increased in adipose tissue samples of obese patients, suggesting an increased capacity for lipolysis inhibition, which may contribute to obesity. The NPR3 is a receptor for the C-type natriurectic peptide (CNP) expressed in adipose tissue (27) . Recently, natriuretic peptides have been identified as a new lipolytic pathway with binding of CNP to its receptor exerting a lipolytic effect (28) . Thus, the reduced mRNA expression of NPR3 detected in the present study is concordant with an impaired lipolytic activity in human obesity. The significantly decreased circulating ADA concentrations observed in the obese patients further reveal a decreased lipolytic rate, since ADA is known to stimulate lipolysis by removing the tonic inhibition exerted by adenosine (29) . Taken together, these findings provide evidence for an impaired lipolytic function in the obese subjects enrolled in our study (Fig. 2) , which could either contribute to the development of obesity or represent an underlying mechanism of action of this disease.
Leptin signaling takes place mainly through activation of Janus kinases (JAK)-signal transducers and activators of transcription (STAT) proteins, especially JAK2 and STAT3 (7). Obesity is characterized by leptin resistance, and a decrease in the activation of JAK2 has been suggested to be involved in this process (30) . The expression of JAK2 in adipose tissue of obese patients was decreased, which may represent an indicator of leptin resistance, at least at the peripheral level.
Blood concentrations of testosterone were similar between the obese and lean groups. However, the microarray study revealed that obese individuals showed a reduced mRNA expression of the AR gene in omental adipose tissue. These results are in agreement with the development of obesity reported in AR deficient mice (31) and suggest that AR deficiency in adipose tissue may be implicated in human obesity.
Several growth factors have been described to be expressed by adipocytes and to exert an effect on adipose tissue (7, 32) . Members of the FGF family are expressed in human adipose tissue and may play a role in the regulation of regional adipose tissue mass (33) . FGF2, 4, and 7, and IGF1 showed a decreased expression in obese patients. These data seem to indicate an attempt to decrease preadipocyte proliferation and adipocyte differentiation (32) . Furthermore, several MAP kinases were shown to be up-regulated, which further supports an inhibition of adipogenesis (34, 35) . This hypothesis is supported by the findings of Nadler et al. (11) , who reported a decrease in the expression of genes normally involved in adipogenesis, a process closely related to obesity. Further studies are needed to address if this may represent a physiological defense mechanism against obesity.
VEGFB and FGF1 are well-recognized inducers of vascularization by acting as endothelial cell growth factors. Omental adipose tissue gene expression of the two known isoforms of VEGF-B was further analyzed in each individual observing that both VEGF-B 167 and VEGF-B 186 mRNA were up-regulated 1.6-and 2.1-fold, respectively. These data indicate that obese patients may have an increased expression of VEGF-B and FGF1 mRNA in omental adipose tissue, which is in accordance with the need for an increased vascularization to support adipose mass enlargement. However, a potential involvement of VEGF-B and FGF1 in angiogenesis and obesity-related endothelial dysfunction needs to be further explored, since the neovascularizating effects of VEGF-B and FGF1 may be counterbalanced by the down-regulation of FIGF, which could have an antiangiogenic effect.
Obesity has been reported to be associated with alterations in the immune function. Obese subjects have an impairment in the responsiveness of lymphocytes, with decreased B and T cell function and low NK cell activity (36) . Fc receptors are known to mediate antibody dependent inflammatory responses and cytotoxicity. Our data show that obese patients have an increased expression of a variety of Fcγ receptors, which may be indicating a counterregulatory response after a depressed IgG function (37) or that the immune function of the obese patients enrolled in our study was not depressed. Our results further show that adipocytes express a wide variety of genes involved in the immune response, thus reinforcing the link between adipose tissue and immunity (38) .
The ratio of observed vs. expected gene density (based on the physical length of each chromosome) indicates a significantly higher value for chromosomes 1, 11, 17, 19, and 22 together with a lower gene density for chromosomes 4, 5, 8, 13, 18, and X (39). Although our findings could be explained by the increased gene density of these chromosomes, some studies have found quantitative trait loci (QTL) affecting BMI or adiposity on chromosomes 1, 11, and 19. Concretely, evidence for the presence of linkage with BMI (40), body fat (41), abdominal subcutaneous fat (42) , and subcutaneous abdominal adipocyte size (43) on chromosome 1 has been published. Similarly, studies reporting evidence of genes influencing BMI (44), body fat (45), energy expenditure (45) , and diabetes (44) coming from markers at chromosome 11 have been reported. Evidence of linkage has also been observed between the LDLR gene on chromosome 19 and adiposity phenotypes (46) . These data are in agreement with our results showing a down-regulation of LDLR gene expression in omental adipose tissue obtained from obese subjects. LDLR is considered to be a primary route of remnant clearance and, when compromised, is known to lead to remnant accumulation in nonobese dyslipidemic phenotypes. The LDLR also has implications in the development of obesity (47, 48) , and a reduced expression of this receptor in omental adipose tissue may further increase the development of dyslipidemia-related obesity or obesity itself. This finding may also underlie the significantly increased circulating LDL-C concentrations observed in our obese patients. Other studies have described linkage with obesity-related phenotypes of markers found on chromosomes 2 (49), 3 (50), 4 (51), 7 (52), 10 (53), 17 (50) , and 20 (54) . Thus, genome-wide scans for obesity genes have not revealed unique regions of linkage. These observations support the notion that obesity is an oligogenic disease influenced by a variety of polygenic factors (modifier genes) as well as by environmental stimuli (55, 56) .
One limitation of the present study is the possibility that some of the detected transcripts are expressed on cellular types different to adipocytes, especially as regards genes involved in the immune response. In this sense, it is interesting to note that some molecules are more abundantly expressed in the stromal-vascular cells of adipose tissue than in adipocytes themselves (57) . However, from a pathophysiological point of view, it is likely that different cell types present in adipose tissue establish bi-directional interactions with adipocytes, thus influencing adipose tissue function and affecting the development or course of obesity. A further limitation lies with the fact that the nature of the study does not allow us to establish whether the observed changes are cause or consequence of obesity. However, knowing the metabolic or signal transduction pathways in which the genes with altered expression are involved, it is reasonable to speculate about their potential implication in the etiopathology of obesity.
In recent years, molecular biology and genetic approaches have helped to unravel some of the complex pathways involved in the regulation of body weight (58) . In this sense, the application of DNA microarrays represents a useful tool for the quick and exhaustive determination of differences in gene expression profiles between physiological and pathological conditions. The present study provides a new view on the study of human obesity unraveling some of the molecular events taking place in omental adipose tissue. Obesity is a complex trait, reflecting the effect of a network of genes influenced at the same time by environmental factors such as diet, exercise, stress, etc. In this context, the present work, which to our knowledge is the first study performed in humans in which obesity-induced gene expression changes are globally analyzed in omental adipose tissue by microarrays, provides valuable new insights into the pathology of human obesity. Contrary to what might have been expected in a rather more simplistic and static concept of obesity, our data clearly show that adipose tissue of obese patients exhibits a quite different expression profile to that of lean individuals from a genomic point of view. The high number and ample spectrum of genes found to be changed in adipose tissue of obese patients substantiate the view of a dramatically different obese adipocyte (Fig. 3) . The complex and complementary nature of the expression profile observed in obese adipose tissue reflects a pleiad of adaptive changes affecting crucial physiological functions that may underlie the difficulties encountered by obese patients to loose weight as well as the high recidivism rate leading to the previously attained obese gene profile. This finding may have relevant implications for the identification of adequate molecular therapeutic targets given the current paucity of anti-obesity drugs available. Antisense 5′-GGTGAGGATCTTCATGAGGT-3′ Genes were classified into categories depending on the putative biological process in which they are involved according to the classification used by the Gene Ontology Consortium (GO) (19) . Genes were classified into categories depending on the putative biological process in which they are involved according to the classification used by the Gene Ontology Consortium (GO) (19) . 
